ArticleEpidemiology and infection2013
Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England.
Article in Epidemiology and infection, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.BMC pulmonary medicine · 2016Pooled it
- Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial.The Lancet regional health. Southeast Asia · 2026Article
- Invasive pneumococcal disease in adults after the introduction of pneumococcal vaccination: a retrospective study in the metropolitan area of Zagreb, Croatia (2010-2022).Frontiers in public health · 2024Article
- Decreasing case fatality rate following invasive pneumococcal disease, North East England, 2006-2016.Epidemiology and infection · 2019Article
- Pneumococcal Conjugate Vaccine impact assessment in Bangladesh.Gates open research · 2018Article
- Implications of asymptomatic carriers for infectious disease transmission and control.Royal Society open science · 2018Article
- Pneumococcal Nasopharyngeal Carriage in Young Healthy Children After Pneumococcal Conjugate Vaccine in Turkey.Balkan medical journal · 2017Article
- Increased Invasive Pneumococcal Disease, North East England, UK.Emerging infectious diseases · 2017Article
- Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease.Epidemiology and infection · 2016Article
- Application of radiation technology in vaccines development.Clinical and experimental vaccine research · 2015Review
- Characteristics of invasive pneumococcal disease in hospitalized children in Austria.European journal of pediatrics · 2014Article
- Increased paediatric hospitalizations for empyema in Australia after introduction of the 7-valent pneumococcal conjugate vaccine.Bulletin of the World Health Organization · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 7-valent pneumococcal conjugate vaccine (PCV7) has been included in the routine childhood immunization programme in the UK since September 2006. A population-based study of serotypes causing invasive pneumococcal disease (IPD) post-PCV7 in North East England was conducted using data from a regional enhanced IPD surveillance system. Overall, there was a 20% reduction [95% confidence interval (CI) 5-32] from 12·1 cases/100 000 population in 2006/2007 to 9·7 in 2009/2010. There was a fall in IPD caused by PCV7 serotypes in all age groups, with reductions of 90% (95% CI 61-99) in children aged <5 years, 50% (95% CI 4-75) in persons aged 5-64 years and 66% (95% CI 40-82) in adults aged ⩾65 years. There was a non-significant increase in IPD caused by non-PCV7 serotypes in children aged <5 years of 88% (95% CI -10 to 312) and adults aged ⩾65 years of 12% (95% CI -19 to 50), which was largely caused by serotypes 7F, 19A and 22F. Replacement disease appears to have reduced the benefits of PCV7 in North East England.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.